Currently predicting for Mon, 1 Apr 2024

Trading levels for ABUS

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 2.64 2.33 %
R2 2.62 1.44 %
R1 2.60 0.89 %
Current price: 2.58
Support S1 2.56 -0.89 %
S2 2.54 -1.44 %
S3 2.52 -2.33 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 2.91 12.79 %
R2 2.88 11.63 %
R1 2.76 6.98 %
Current price 2.58
Support S1 2.54 -1.55%
S2 2.50 -3.10%
S3 2.49 -3.49%

ABUS Predictions History

4 years ago
OxanaKaliko133652 predicted that ABUS for 2020-01-13 is going

Rank:

4 years ago
NameNotImportant predicted that ABUS for 2019-05-06 is going $2.54 (-3.42%)

4 years ago
NameNotImportant predicted that ABUS for 2019-04-29 is going $2.92 (10.61%)

5 years ago
JS predicted that ABUS for 2019-02-01 is going $3.65 (-5.68%)

5 years ago
HoodedMonk predicted that ABUS for 2018-09-28 is going $10.08 (3.92%)

Rank:

5 years ago
Susan.Stiteler.22573 predicted that ABUS for 2018-07-17 is going $12.30 (5.13%)

Rank:

6 years ago
JS predicted that ABUS for 2018-03-12 is going $5.92 (2.07%)

6 years ago
Ryan predicted that ABUS for 2018-03-12 is going $5.78 (-0.34%)

Rank:

6 years ago
bbullish2 predicted that ABUS for 2018-01-29 is going $5.27 (0.38%)

6 years ago
PumpTheseNumbers predicted that ABUS for 2018-01-29 is going $5.33 (1.52%)

Click to get the best stock tips daily for free!

About Arbutus Biopharma Corporation

Arbutus Biopharma Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel ... ABUS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT